Brett Guthrie

Thank you, Chair DeGette, for holding this hearing.

the most recent data from the National Youth Tobacco Survey is alarming.

I share your concern about youth vaping trends that have emerged in the United States in recent years.

The U.S. Surgeon General has called e-cigarette use by youth an epidemic and warned that it threatens decades of progress towards ensuring that fewer young people use tobacco.

The marketing of e-cigarette products to children must stop, and youth access to e-cigarette products must be prevented.

We believe this authority is important to protect the integrity of the supply chain.

I was proud to introduce three bipartisan bills today.

The Safeguarding Therapeutics Act introduced by Representative Brett Guthrie will protect against counterfeit medical devices.

We are cooperating closely with their criminal investigation teams.

We appreciate the leadership of Representatives Guthrie and Engel on this issue.

Congress needs to continue supporting the states, and this Committee needs to continue conducting oversight of these critical issues.

This hearing is a critical opportunity for us to check in with the states, those that are on the front lines battling the nation's opioid epidemic.

Our local communities are suffering. On average, 130 Americans die every day from an opioid overdose.

The good news is that each state testifying before us today has seen a decrease in their overdose death rates.

I thank the gentleman for yielding. Madam Speaker, I rise today to bring attention to the consequences of the drug pricing bill H.R. 3. There is no doubt we must act to lower prescription drug prices for Americans and for Americans to pay…

I thank the gentleman for yielding. I rise today in opposition to H.R. 3. Two of the issues that I often hear about back home are robocalls and drug prices. Last week, despite ideological differences on both sides of the aisle, we came…

I am disappointed that this week we are going to go through--pursue partisan legislation on the floor instead of bipartisan policies that have broad support.

Thank you, Chair DeGette, for holding this very important hearing.

I look forward to working with my colleagues to advance bipartisan reform that will actually lower drug prices while preserving innovative research.

The adequacy of FDA's oversight of the U.S. drug supply has been a longstanding issue for this committee.

The flu is a leading cause of death in the United States.

The President offered to sign TPS and he offered to sign DACA if he could come up with a deal on our funding.

Congress needs to address this problem as well.

I appreciate the administration's commitment to improving our flu preparedness.

Thank you very much. Thank you, Chair DeGette, for holding this hearing on such an important issue.